Notwithstanding promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from PBMs. The companies are frequently erecting barriers to access, including high expense criteria and prior authorization that hinder user availability. Market suggest that suc